Heated Intravesical Chemotherapy: Biology and Clinical Utility

Wei Phin Tan; Thomas A Longo; Brant A Inman

doi:10.1016/j.ucl.2019.09.008

Heated Intravesical Chemotherapy: Biology and Clinical Utility

Urol Clin North Am. 2020 Feb;47(1):55-72. doi: 10.1016/j.ucl.2019.09.008.

Authors

Wei Phin Tan¹, Thomas A Longo¹, Brant A Inman²

Affiliations

¹ Division of Urology, Duke University Medical Center, Durham, NC 27710, USA.
² Division of Urology, Duke University Medical Center, Durham, NC 27710, USA. Electronic address: brant.inman@duke.edu.

Abstract

Non-muscle-invasive bladder cancer can be a challenging disease to manage. In recent years, hyperthermia therapy in conjunction with intravesical therapy has been gaining traction as a treatment option for bladder cancer, especially if Bacillus Calmette-Guerin might not be available. Trials of intravesical chemotherapy with heat are few and there has been considerable heterogeneity between studies. However, multiple new trials have accrued and high-quality data are forthcoming. In this review, we discuss the role of combined intravesical hyperthermia and chemotherapy as a novel approach for the treatment of bladder cancer.

Keywords: Bladder hyperthermia; HIVEC; Heated chemotherapy; Heated mitomycin; Intravesical chemotherapy; Intravesical mitomycin.

Publication types

Review

MeSH terms

Administration, Intravesical
Antibiotics, Antineoplastic / administration & dosage
Humans
Hyperthermia, Induced / methods*
Mitomycin / administration & dosage*
Treatment Outcome
Urinary Bladder Neoplasms / therapy*

Substances

Antibiotics, Antineoplastic
Mitomycin

Abstract

Publication types

MeSH terms

Substances

Grants and funding